{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:58:54Z","timestamp":1780419534614,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116358","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T02:48:23Z","timestamp":1711680503000},"page":"116358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH"],"prefix":"10.1016","volume":"270","author":[{"given":"Ya","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116358_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116358_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2012.128","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"107","author":"Chalasani","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2024.116358_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116358_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116358_bib5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116358_bib6","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17512433.2021.1884068","article-title":"An update on drug development for the treatment of nonalcoholic fatty liver disease \u2013 from ongoing clinical trials to future therapy","volume":"14","author":"Rau","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116358_bib10","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/ijms24032844","article-title":"Advances in the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"24","author":"Yin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116358_bib11","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116358_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.plipres.2004.05.001","article-title":"Fatty acid-binding proteins - insights from genetic manipulations","volume":"43","author":"Haunerland","year":"2004","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116358_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.nutr.27.061406.093710","article-title":"The emerging functions and mechanisms of mammalian fatty acid\u2013binding proteins","volume":"28","author":"Storch","year":"2008","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ejmech.2024.116358_bib14","article-title":"Association of a human FABP1 gene promoter region polymorphism with altered serum triglyceride levels","volume":"10","author":"Aspichueta","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116358_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/MCO.0000000000000031","article-title":"Fatty acid binding proteins","volume":"17","author":"Thumser","year":"2014","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.ejmech.2024.116358_bib16","article-title":"Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults","volume":"7","author":"Xu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116358_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0006-291X(72)90931-X","article-title":"The binding of fatty acids to cytoplasmic proteins: binding to Z protein in liver and other tissues of the rat","volume":"47","author":"Mishkin","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116358_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI107768","article-title":"Fatty acid-binding protein in small intestine. Identification, isolation, and evidence for its role in cellular fatty acid transport","volume":"54","author":"Ockner","year":"1974","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2024.116358_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.07.027","article-title":"SnapShot: FABP functions","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116358_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1043-2760(00)00257-5","article-title":"The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function","volume":"11","author":"Hertzel","year":"2000","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116358_bib21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0006-291X(86)90314-1","article-title":"Tissue expression of three structurally different fatty acid binding proteins from rat heart muscle, liver, and intestine","volume":"137","author":"Bass","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116358_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9120(03)00096-1","article-title":"Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility","volume":"36","author":"Pelsers","year":"2003","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejmech.2024.116358_bib23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.bbalip.2013.05.008","article-title":"High glucose potentiates L-FABP mediated fibrate induction of PPAR\u03b1 in mouse hepatocytes","volume":"1831","author":"Petrescu","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2024.116358_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jnutbio.2010.01.005","article-title":"Liver fatty acid-binding protein and obesity","volume":"21","author":"Atshaves","year":"2010","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ejmech.2024.116358_bib25","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1194\/jlr.R056705","article-title":"Recent insights into the biological functions of liver fatty acid binding protein 1","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116358_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/2211-5463.12240","article-title":"Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease","volume":"7","author":"Mukai","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2024.116358_bib27","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1211\/0022357044111","article-title":"Effect of dexamethasone, 2-bromopalmitate and clofibrate on L-FABP mediated hepatoma proliferation","volume":"56","author":"Rajaraman","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116358_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF00666102","article-title":"Modulation of mitogenesis by liver fatty acid binding protein","volume":"13","author":"Sorof","year":"1994","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2024.116358_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1010851130136","article-title":"Expression of liver fatty acid binding protein alters growth and differentiation of embryonic stem cells","volume":"219","author":"Schroeder","year":"2001","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2024.116358_bib30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/hep.22927","article-title":"Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease","volume":"49","author":"Charlton","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bbalip.2012.12.014","article-title":"The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPAR\u03b1; and repressed by C\/EBP\u03b1: implications in FABP1 down-regulation in nonalcoholic fatty liver disease","volume":"1831","author":"Guzm\u00e1n","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2024.116358_bib32","doi-asserted-by":"crossref","first-page":"G164","DOI":"10.1152\/ajpgi.00369.2013","article-title":"Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-\u03b1 activation in cultured human female hepatocytes","volume":"307","author":"McIntosh","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejmech.2024.116358_bib33","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1194\/jlr.M900058-JLR200","article-title":"L-FABP directly interacts with PPAR\u03b1 in cultured primary hepatocytes","volume":"50","author":"Hostetler","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116358_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbalip.2017.12.013","article-title":"Ablating both Fabp1 and Scp2\/Scpx (TKO) induces hepatic phospholipid and cholesterol accumulation in high fat-fed mice","volume":"1863","author":"Milligan","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2024.116358_bib35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/1940-6207.CAPR-13-0120","article-title":"Liver fatty acid-binding protein (L-Fabp) modifies intestinal fatty acid composition and adenoma formation in ApcMin\/+ mice","volume":"6","author":"Dharmarajan","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.ejmech.2024.116358_bib36","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/hep.26318","article-title":"Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib37","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1194\/jlr.M020966","article-title":"Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp(-\/-) mice","volume":"53","author":"Newberry","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116358_bib38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.21369","article-title":"Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice","volume":"44","author":"Newberry","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib39","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1002\/ptr.7839","article-title":"Echinocystic acid prevents obesity and fatty liver via interacting with FABP1","volume":"37","author":"Xiao","year":"2023","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2024.116358_bib40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2023.07.026","article-title":"Derlin-1 ameliorates nonalcoholic hepatic steatosis by promoting ubiquitylation and degradation of FABP1","volume":"207","author":"You","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2024.116358_bib41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejmech.2017.07.022","article-title":"Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review","volume":"138","author":"Floresta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116358_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/13543776.2016.1182500","article-title":"Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015)","volume":"26","author":"Wang","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116358_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/abio.1996.0028","article-title":"A simple assay for intracellular lipid-binding proteins using displacement of 1-anilinonaphthalene 8-sulfonic acid","volume":"233","author":"Kane","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2024.116358_bib44","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/jm701192w","article-title":"Characterization of the drug binding specificity of rat liver fatty acid binding protein","volume":"51","author":"Chuang","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116358_bib45","doi-asserted-by":"crossref","first-page":"113720","DOI":"10.1016\/j.ejmech.2021.113720","article-title":"Development of FABP4\/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus","volume":"224","author":"He","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116358_bib46","doi-asserted-by":"crossref","first-page":"H971","DOI":"10.1152\/ajpheart.00360.2018","article-title":"Fatty acid-binding protein 3 contributes to ischemic heart injury by regulating cardiac myocyte apoptosis and MAPK pathways","volume":"316","author":"Zhuang","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2024.116358_bib47","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1021\/acs.jmedchem.9b02107","article-title":"Exploration of fragment binding poses leading to efficient discovery of highly potent and orally effective inhibitors of FABP4 for anti-inflammation","volume":"63","author":"Su","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116358_bib48","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1074\/jbc.RA118.006848","article-title":"A ligand-induced structural change in fatty acid\u2013binding protein 1 is associated with potentiation of peroxisome proliferator\u2013activated receptor \u03b1 agonists","volume":"294","author":"Patil","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116358_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116358_bib50","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000033","article-title":"The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance","volume":"7","author":"Gill","year":"2023","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.ejmech.2024.116358_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116358_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13158","article-title":"Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1\u03b1\/SLC7A11 pathway","volume":"55","author":"Yuan","year":"2022","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejmech.2024.116358_bib54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116358_bib55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/hep.31031","article-title":"Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets","volume":"72","author":"Hwang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib56","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116358_bib57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2024.116358_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/antiox11010091","article-title":"Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease","volume":"11","author":"Ma","year":"2021","journal-title":"Antioxidants"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:10:36Z","timestamp":1738411836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":58,"alternative-id":["S0223523424002381"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116358","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116358"}}